a b s t r a c t DNA methylation occurs at the CpG residues and serves as a powerful epigenetic mechanism that negatively regulates gene expression. This process is catalyzed by DNA methyltransferases and occurs within ''CpG islands'' found in the promoter regions of >70% of human genes. Given the important role of DNA methylation in regulating gene expression, un-programmed changes in methylation patterns are expected to either silence or activate transcription of tumor suppressor genes (via hypermethylation) or oncogenes (via demethylation), respectively, and by doing so promote a disease state. In light of the fact that a number of different cancers are frequently associated with hypermethylated tumor suppressor genes together with the observation that tumor derived genomic DNAs are present in various body fluids including serum/plasma, urine, sputum and bronchial lavage, methylated DNA has shown tremendous promise to serve as a robust biomarker for detecting cancer. Over the last several years protocols for capturing small amounts of DNA in circulation have been developed. Once captured, DNA methylation may be readily monitored by restriction enzyme digestion or bisulfite conversion followed by amplification of the desired genomic region with the polymerase chain reaction (PCR). New technologies which employ methyl-binding protein or antibodies that bind specifically to methylated-CpG residues have now enabled investigators to interrogate the status of entire ''DNA methyome'' of diseased tissue in an efficient and cost-effective manner. In this review, we describe the various tumor suppressor genes that are frequently hypermethylated in different cancers and how these and other methylated loci may be employed as clinically useful biomarkers for diagnosing cancer noninvasively using readily available body fluids.
Introduction
In humans DNA methylation occurs in the dinucleotide 5 0 -CpG-3 0 . It has been estimated that over 70% of genes harbor regions called ''CpG islands'' in which the frequency of CpG is considerably higher than expected. A vast majority of CpG islands are found in the upstream promoter regions of genes but in others they are located downstream of the transcription start point. Methylation at CpG dinucletode is catalyzed by three major DNA methylatransferases namely DNMT1, DNMT3a and DNMT3b which covalently attach a methyl group to the C5 position of cytosine residues. DNMT1 is responsible for maintaining genomic DNA methylation patterns and employs hemi-methylated-CpG dinucleotides, produced after DNA replication or repair, as substrate and fully methylates them. DNMT3a and 3b methylate previously unmodified CpG residues and hence are known as de novo methylases.
Since DNA methylation silences gene transcription such modifications must be carefully orchestrated during the course of development to ascertain that expression of certain sets of genes is spatially and temporally restricted to specific cell-types. DNA methylation patterns are tissue-specific and ''frozen'' once development is complete. Un-programmed changes in DNA methylation patterns brought about by gain or loss of function in any of the DNA methyltransferases or demethylases are likely to lead to developmental defects in the growing embryo or a disease state in individuals by altered expression of oncogenes and/or tumor suppressor genes. Nutrition also impacts genomic DNA methylation patterns. Since S-adenosylmethionine (SAM) serves as the source of methyl group which is recycled through the folate and cobalamin dependent pathways, 1 DNA methylation patterns are dynamic during embryogenesis. Around the eight cell embryonic stage, genomic methylation patterns are erased but are then re-established during the implantation stage of the embryo 5 ; subsequent embryonic development is associated with additional waves of DNA methylation and demethylation. 5, 6 The biochemical signals responsible for promoting such dramatic fluctuations in DNA methylation patterns, be they local or global, remain unknown. In adults, distribution of genomic methylation marks is cell type specific and any un-programmed changes in these patterns have been linked to aging and disease. 7 
Role of DNA methylation in disease
Given the important role DNA methylation plays in regulating and restricting the expression of genes to certain cell-types, it is expected that aberrant changes in DNA methylome are likely to promote a disease state. Although infections as well as environmental factors are known to influence DNA methylation patterns, the mechanisms by which they impact the activity or targeting of DNA methyltransferases, MBDs and/or demethylases to different genomic regions remains unclear. There is now strong evidence suggesting that cardiovascular disease, hypertension, stroke, depression and type-2 diabetes originate early in development because of repeated environmental insults that influence the epigenome. 8 Similarly, neurological disorders such as schizophrenia, bipolar disorder and autism are associated with un-programmed changes in the epigenome.
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Aberrant DNA methylation has also been found to play an important role in cancer development and progression. Genomewide hypomethylation that is restricted largely to gene-poor regions as well as gene-specific hypermethylation of CpG islands are the two commonest forms of epigenomic modifications that are frequently observed in cancer cells. 12, 13 Hypomethylation of centromeric DNA promotes genomic instability and appears to increase as cancers progress from non-metastatic to metastatic state. [14] [15] [16] [17] Cancer cell genomes invariably harbor one or more tumor suppressor genes that are hypermethylated. For instance, silencing of Rb by DNA hypermethylation in retinoblastomas was among the first reports which described how a gene may be inactivated epigenetically. 18 Subsequently, a number of other tumor suppressor genes such as VHL, p16, BRCA and hMLh1 have also been found to be hypermethylated in cancers. 19, 20 Table 1 provides a list of all genes whose promoters have been found to be hypermethylated in various cancers.
Using methylated DNA in circulation as cancer biomarker
Clinical utility of even a reliable disease-specific biomarker is undermined if the tissue to be screened requires surgical removal. The ideal biomarker therefore is one which is found in readily available biological samples that can be obtained noninvasively. Due to the high cellular turnover, cancer patients carry elevated levels of free DNA (w200 ng/ml) in their blood. 25 Other body fluids such as urine, 26 bronchoalveolar lavage (BAL), 27 mammary aspiration fluids, 28 saliva, 29 sputum 27 and stools 30 that contact tumors are also potential sources of cancer cell DNA. These circulatory DNAs from blood or other body fluids can be captured easily and the status of DNA methylation at various gene promoters interrogated by various methods. According to one study 77% of prostate cancer patients showed GSTP1 hypermethylation in the DNA which was derived from urine as compared to a detection rate of 72% in plasma/serum samples. 31 Similarly, analysis of genomic DNA purified from the sputum of lung cancer patients found p16 to be most frequently methylated. 27, 33 Studies using bronchoalveolaer lavage from early stage lung cancer patients have revealed frequent DNA methylation at p16, RARb, DAPK and MGMT gene promoters. 34 Ductal lavage fluid and needle aspirates are also useful sources of tumor DNA which could be employed for detecting breast cancers. 28, 35 Krassenstein et al. have found a number of genes which were abnormally methylated in genomic DNAs obtained from nipple aspirates of breast cancer patients. 35 Abnormally methylated DNAs are also found in the saliva from head and neck, and in stool samples from colon and rectal cancer patients. 29, 30 Similarly, bladder cancer patients excrete urine that contains hypermethylated DAPK, RARb, E-cadherin and p16 CpG islands; on their own these biomarkers were found to be unreliable but when combined together yielded an impressive detection rate of 91%.
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Using serum samples from non-small cell lung cancer (NSLC) patients, Esteller et al found 15 out of 22 cancer patients to be positive for DNA methylation at p16, DAPK, GSTP1 or MGMT gene promoters, 21 however, detection rates of NSLCs varied from 6% to 76% when only p16 was used as a DNA methylation marker. [22] [23] [24] DNA methylation markers that are specific for different cancers are obviously much sought after because if identified they will enable investigators to accurately predict different types of cancers. Until such cancer-specific DNA methylation markers are found, studies have shown that employing a panel of different DNA methylation biomarkers (i.e., several gene-specific CpG islands) is considerably more reliable for predicting cancer phenotypes as compared to using just one.
Methods for determining DNA methylation status of genes
Clinically ideal diagnostic tests are those which can be carried out on readily accessible body fluids (e.g., serum, urine, saliva, etc.). Such tests should be sensitive, specific, reproducible, cost-effective, and be of turn-key nature requiring minimal number of steps so that it could be carried out in a high-throughput manner. Body fluids of cancer patients serve an excellent source of tumor derived genomic DNA which can be used for interrogating the DNA methylation status of either a select panel of genes or the entire genome using a number of different methods. However since these samples invariably contain large amounts of background DNA from normal cells it is essential that the employed diagnostic test be sensitive enough to detect the few available copies of methylated DNA present in the sample.
Initially, DNA methylation sensitive and insensitive restriction endonucleases (e.g., HpaII and Msp1, respectively) were employed for detecting CpG methylation at specific genomic loci but since this approach requires large amounts of genomic DNA it is not deemed practical for clinical use. Over the past decade, a number of very sensitive as well as reliable methods have been developed which now allow investigators to detect locus-specific DNA methylation from very small amounts of genomic DNA. Among these, methylation-specific PCR (MSP) has been used most commonly. 36 In this assay, genomic DNA is treated with sodium bisulfite which deaminates unmodified cytosines (C) to uracil but spares methylated cytosines. This step converts all epigenetic information into DNA sequence information. The chemically converted DNA is subsequently subjected to polymerase chain reaction (PCR) using primer sets that are strategically designed to anneal to a specific region within a CpG island of interest and capable of differentiating methylated from unmethylated gene promoters. Although MSP is user-friendly and can detect DNA methylation with impressive sensitivity, it is neither quantitative nor can be performed in a high-throughput manner. Another disadvantage of MSP is that it allows screening of only a very small stretch (i.e. <40 bp) of DNA within a CpG island for methylated residues. These shortcomings render MSP ineffective in a clinical setting where the amount of methylated DNA sometimes needs to be correlated with disease severity for prognosis and where a number of genes need to be analyzed simultaneously. DNA sequencing of PCR products generated from primers flanking a CpG island of interest using bisulfite converted DNA as template offers the highest resolution in terms of providing detailed information about the methylated state of an entire CpG island, but its labor intensive protocol and expense precludes its use as a diagnostic tool. Alternatively, a specific CpG island may be PCR amplified using bisulfite converted DNA and the methylated-CpGs within it detected and scored via restriction enzyme analysis. This strategy forms the basis of another useful DNA methylation detection technique known as combined bisulpite restriction analysis (COBRA). [37] [38] [39] In COBRA, sequence changes in DNA that result as a consequence of bisulphite-conversion are analyzed through restriction enzyme digestion of the resulting PCR product. 39 The main limitation of this approach is that it is only useful for probing DNA methylation status of those CpGs that are harbored within a restriction enzyme site. Methylight is another method capable of detecting methyated and unmmethylated DNA with exquisite sensitivity. This assay makes use of Taqman probes which anneal in between the two PCR primers and hence report DNA amplification in real-time. Since the probe contains a fluorophore at the 5 0 end and a quencher on either the 3 0 end or in the middle, no fluorescence is emitted in the intact probe upon excitation. During the extension phase of PCR the probe is cleaved by the 5 0 /3 0 exonuclease activity of Taq DNA polymerase which distances the fluorophore from the quencher and results in a fluorescent signal that is proportional to the amount of the generated PCR product. In this procedure, two different primer pairs are used to amplify bifulfite converted DNA: one which is specific for methylated DNA and the other specific for unmethylated DNA. Depending on the requirement, methylight assays may be performed either in a quantitative or semi-quantitative format, and report nucleic acid amplification in real-time without requiring gel electrophoresis. 40 Additionally these assays are user-friendly and amenable to automation.
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DNA methylation-specific microarrays are useful for interrogating the entire epigenome in an open-minded way. 42, 43 In this procedure, genomic DNA obtained from diseased tissue or body fluid is sheared and an antibody (or an MBD) with high affinity for 5-methylcytosine employed to selectively capture those genomic fragments that are methylated. After labeling, this population of DNAs is hybridized to a gene array in which all genomic CpG islands are represented. This powerful approach, albeit costly at present, is capable of identifying hundreds of specific genomic loci simultaneously that may be aberrantly methylated in different types of cancer. Additionally, this approach may also prove to be useful for monitoring cancers during or after treatment. Table 2 lists the DNA methylation detection methods discussed herein and their respective features.
Conclusion
Work over the past decade has shown that DNA methylation biomarkers can not only detect cancer at an early stage but may also be useful for monitoring disease progression during or after treatment. Since tumor derived DNAs are found in various body fluids of cancer patients, they can be obtained noninvasively and screened using various methods to probe presence or absence of DNA methylation at specific loci. Although a number of DNA methylation biomarkers have been identified to date none are reliable enough to be clinically useful. However, development of sophisticated new technology platforms and reagents should eventually lead to the identification of discrete sets of DNA methylation markers (i.e., ''signatures'') that are unique to different types of cancers. The clinical utility of DNA methylation markers for diagnosing cancers at an early stage therefore looks promising. 
